Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

World Journal of Surgical Oncology

Tomonori Habuchi¹  Hiroshi Nanjyo³  Shigeru Satoh¹  Yohei Horikawa¹  Takamitsu Inoue¹  Mitsuru Saito¹  Hiroshi Tsuruta¹  Takashi Obara¹  Kazuyuki Numakura¹  Shinya Maita¹  Teruaki Kumazawa²  Norihiko Tsuchiya¹  Shintaro Narita¹ 

[1] Department of Urology, Akita University School of Medicine, Akita, Japan;Department of Urology, Senboku General Hospital, Daisen, Japan;Department of Pathology, Akita University School of Medicine, Akita, Japan

关键词: androgen deprivation;    complete androgen blockade;    estramustine phosphate;    docetaxel;    prostate cancer;    chemohormonal therapy;   

Others  :  828125
DOI  :  10.1186/1477-7819-10-1

 received in 2011-09-07, accepted in 2012-01-04,  发布年份 2012

【 摘 要 】

Background

To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).

Methods

Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m²) with estramustine phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed.

Results

No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease.

Conclusion

We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.

【 授权许可】

   
2012 Narita et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
• [2]Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC: What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76:710-714.
• [3]D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998, 280:969-974.
• [4]Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998, 160:2428-2434.
• [5]Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD: A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009, 35:9-17.
• [6]Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
• [7]Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
• [8]Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA: Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004, 63:1138-1142.
• [9]Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233-5240.
• [10]Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P: Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007, 100:274-280.
• [11]Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME: Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008, 180:565-570. discussion 570
• [12]Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A: Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008, 71:323-327.
• [13]Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, et al.: Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009, 101:1248-1252.
• [14]Miyake H, Fujimoto H, Komiyama M, Fujisawa M: Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer. Eur J Surg Oncol 36:281-286.
• [15]Freiha FS, Salzman J: Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy. J Urol 1977, 118:616-617.
• [16]pathology JUAtJso: General rule for clinical and pathological studies on prostate cancer. 4th edition. Tokyo: Kanehara; 2010.
• [17]Sitka Copur M, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L, Wendt J: Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001, 28:16-21.
• [18]Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME: Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005, 11:4905-4911.
• [19]Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567.